Perioperative bridging of oral anticoagulation therapy;Überbrückung der oralen antikoagulation bei interventionellen eingriffen

Deutsches Arzteblatt

Volumn 104, Issue 18, 2007, Pages

  Bauersachs, Rupert M ^a   Schellong, Sebastian ^b   Haas, Sylvia ^c   Gogarten, Wiebke ^d   Riess, Hanno ^e   Omran, Heyder ^f  

^a KLINIKUM DARMSTADT   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f ST MARIEN HOSPITAL   (Germany)

Author keywords

Bridging; Low molecular heparin; Oral anticoagulation; Recommendation; Risk; Vitamin K antagonist

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; MEDICAL PRACTICE; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

EID: 34447274746     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Douketis JD, Johnson JA, Turpie AG: Low-molecular-weight-heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164:1319-26.
2. Jafri SM: Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. Am Heart J 2004; 147: 3-15.
3. Spandorfer J: The management of anticoagulation before and after procedures. Med Clin North Am 2001; 85: 1109-16.
4. Omran H, Hammerstingl C, Schmidt H, von der Recke G, Paar WD, Luderitz B: A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization. Thromb Haemost 2003; 90: 267-71.
5. Dunn AS, Turpie AG: Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003; 163: 901-8.
6. Mehra P, Cottrell DA, Bestgen SC, Booth DF: Management of heparin therapy in the high-risk, chronically anticoagulated, oral surgery patient: a review and a proposed nomogram. J Oral Maxillofac Surg 2000; 58: 198-202.
7. Gerson LB, Gage BF, Owens DK, Triadafilopoulos G: Effect and outcomes of the ASGE guidelines on the periendoscopic management of patients who take anticoagulants. Am J Gastroenterol 2000; 95: 1717-24.
8. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB: An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81: 2-10.
9. Wahl MJ: Dental surgery in anticoagulated patients. Arch Intern Med 1998; 158: 1610-6.
10. Montalescot G, Polle V, Collet JP et al.: Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000; 101: 1083-6.
11. Stellbrink C, Nixdorff U, Hofmann T et al.: Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anti-coagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109: 997-1003.
12. Fanikos J, Tsilimingras K, Kucher N, Rosen AB, Hieblinger MD, Goldhaber SZ: Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol 2004; 93: 247-50.
13. Halbritter KM, Wawer A, Beyer J, Oettler W, Schellong SM: Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1 year registry of 311 episodes. J Thromb Haemost 2005; 3: 2823-5.
14. Spyropoulos A, Dunn A, Turpie A et al.: Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical heart valves on long term oral anticoagulants: Results from the REGIMEN registry [abstract A832]. J Am Coll Cardiol 2005; 45: 352.
15. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin-K-antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204-33.
16. Kearon C, Hirsh J: Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-11.
17. Kearon C: Long-term management of patients after venous thromboembolism. Circulation 2004; 110: 10-8.
18. Katholi RE, Nolan SP, McGuire LB: The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. Am Heart J 1978; 96: 163-5.
19. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ: Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84: 478-80.
20. Johnson JA, Turpie AG: Temporary discontinuation of oral anticoagulants: role of low-molecular-weight heparin. Thromb Haemost 2001; 85: 2323.
21. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J: Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003; 89: 527-30.
22. Omran H, Hammerstingl C, Schmidt H, Lüderitz B: Periinterventionelles Management bei oral antikoagulierten Patienten [Abstract L6]. Hämostaseologie 2005; 25(1): 1-54.
23. Dunn A, Spyropoulos A, Sirko S, Turpie A: Perioperative bridging therapy with enoxaparin in patients requiring interruption of long term anticoagulant therapy: a multicentre cohort study. Blood 2004; 104(abstract) 1761.
24. Hammerstingl C, Schlang G, Bernhardt P, Schmidt H, Omran H: Einsetzbarkeit niedermolekularer Heparine bei Umstellung einer oralen Antikoagulation vor Interventionen mit erhöhtem Blutungsrisiko: Das "Bonn-Register" - Erfahrungen mit 200 Patienten. Z Kardiol 2004; 93(Suppl): 281-2.
25. Kovacs MJ, Kearon C, Rodger M et al.: Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110: 1658-63.